Literature DB >> 9436557

PET scan predicts recovery of left ventricular function after coronary artery bypass operation.

W J Flameng1, B Shivalkar, B Spiessens, A Maes, J Nuyts, J VanHaecke, L Mortelmans.   

Abstract

BACKGROUND: Viable but hypocontractile myocardium can show functional improvement after revascularization (hibernation). It is sometimes difficult, however, to predict viability and recovery in patients with severe left ventricular function. This study sought to identify possible predictive factors of recovery of cardiac function after revascularization in patients with three-vessel disease.
METHODS: Positron emission tomography (fluoro-18-deoxyglucose uptake for metabolism; nitrogen 13-labeled ammonia for flow) and equilibrium-gated nuclear angiography (for the global ejection fraction) were performed in 59 patients with three-vessel disease before and after undergoing coronary artery bypass grafting. The positron emission tomographic data were expressed as match normal (flow and metabolism normal), mismatch (low flow, high metabolism), match viable (moderate decrease in flow and metabolism), and match necrosis (low flow and metabolism).
RESULTS: Stepwise logistic regression analysis showed that only mismatch regions played a significant role in predicting postoperative improvement in function (p = 0.019). There were 1.7 +/- 1.5 mismatch regions in 31 patients who showed an improvement in their ejection fraction (0.47 +/- 0.14 versus 0.58 +/- 0.11; mean +/- standard deviation) versus 0.8 +/- 1.0 mismatch regions (p = 0.017) in patients who did not show recovery. There was more pronounced functional improvement with increasing numbers of mismatch regions, and patients with at least one mismatch region had a high likelihood of recovery (p < 0.001). In patients with a very low preoperative ejection fraction and two or more mismatch regions, there was early significant recovery (0.27 +/- 0.08 versus 0.46 +/- 0.06; p = 0.009).
CONCLUSIONS: At least one mismatch region must be present for there to be a postoperative functional benefit. When a low left ventricular ejection fraction is associated with mismatch, early recovery is substantial.

Entities:  

Mesh:

Year:  1997        PMID: 9436557     DOI: 10.1016/s0003-4975(97)00919-3

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  PET myocardial perfusion and glucose metabolism imaging: Part 2-Guidelines for interpretation and reporting.

Authors:  Heinrich R Schelbert; Robert Beanlands; Frank Bengel; Juhani Knuuti; Marcelo Dicarli; Josef Machac; Randolph Patterson
Journal:  J Nucl Cardiol       Date:  2003 Sep-Oct       Impact factor: 5.952

2.  Assessment of myocardial viability: more than measurements of radiotracer uptake alone.

Authors:  James A Arrighi
Journal:  J Nucl Cardiol       Date:  2006 Mar-Apr       Impact factor: 5.952

3.  Comparison of nitrate augmented Tc-99m tetrofosmin gated SPECT imaging with FDG PET imaging for the assessment of myocardial viability in patients with severe left ventricular dysfunction.

Authors:  Senthil Raja; Baljinder Singh; Manoj Kumar Rohit; Kuruva Manohar; Raghava Kashyap; Anish Bhattacharya; B R Mittal
Journal:  J Nucl Cardiol       Date:  2012-08-08       Impact factor: 5.952

Review 4.  Chronic ischemic left ventricular dysfunction: from pathophysiology to imaging and its integration into clinical practice.

Authors:  Shahbudin H Rahimtoola; Vasken Dilsizian; Christopher M Kramer; Thomas H Marwick; Jean-Louis J Vanoverschelde
Journal:  JACC Cardiovasc Imaging       Date:  2008-07

5.  Positron emission tomography myocardial perfusion and glucose metabolism imaging.

Authors:  Josef Machac; Stephen L Bacharach; Timothy M Bateman; Jeroen J Bax; Robert Beanlands; Frank Bengel; Steven R Bergmann; Richard C Brunken; James Case; Dominique Delbeke; Marcelo F DiCarli; Ernest V Garcia; Richard A Goldstein; Robert J Gropler; Mark Travin; Randolph Patterson; Heinrich R Schelbert
Journal:  J Nucl Cardiol       Date:  2006-11       Impact factor: 3.872

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.